Cellectis (0WA2) Stock Overview
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0WA2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.83 |
| 52 Week High | €4.84 |
| 52 Week Low | €1.13 |
| Beta | 2.85 |
| 1 Month Change | -22.81% |
| 3 Month Change | -31.18% |
| 1 Year Change | 130.80% |
| 3 Year Change | 53.16% |
| 5 Year Change | -83.88% |
| Change since IPO | -88.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0WA2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.7% | -4.1% | -0.9% |
| 1Y | 130.8% | 18.9% | 15.0% |
Return vs Industry: 0WA2 exceeded the UK Biotechs industry which returned 18.9% over the past year.
Return vs Market: 0WA2 exceeded the UK Market which returned 15% over the past year.
Price Volatility
| 0WA2 volatility | |
|---|---|
| 0WA2 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.0% |
Stable Share Price: 0WA2 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0WA2's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 219 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
Cellectis S.A. Fundamentals Summary
| 0WA2 fundamental statistics | |
|---|---|
| Market cap | €206.88m |
| Earnings (TTM) | -€58.63m |
| Revenue (TTM) | €69.04m |
Is 0WA2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0WA2 income statement (TTM) | |
|---|---|
| Revenue | US$79.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$79.59m |
| Other Expenses | US$147.19m |
| Earnings | -US$67.59m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 100.00% |
| Net Profit Margin | -84.92% |
| Debt/Equity Ratio | 67.5% |
How did 0WA2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 21:59 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellectis S.A. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Jack Allen | Baird |
| Amanda Murphy | BTIG |